Our goal is to improve the lives of patients from early childhood through adulthood by leveraging our pharmaceutical and clinical development expertise to develop paediatric friendly therapeutics that answer critical unmet medical needs in the field of rare and neglected diseases.
Our lead product
Our most advanced product is ADV7103, an innovative combination product, is being developed for the treatment of distal Renal Tubular Acidosis (dRTA), an orphan nephrology indication.
Because orphan diseases affect people from early childhood to adulthood, Advicenne makes a point of designing and developing medicines in dosage forms that are suitable for both children and adults.
To keep updated with Advicenne’s latest news announcements.
Advicenne is a biopharmaceutical company
focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications